Evading pre-existing anti-hinge antibody binding by hinge engineering.

ABSTRACT: Antigen-binding fragments (Fab) and F(ab')₂ antibodies serve as alternative formats to full-length anti-bodies in therapeutic and immune assays. They provide the advantage of small size, short serum half-life, and lack of effector function. Several proteases associated with invasive diseases are known to cleave antibodies in the hinge-region, and this results in anti-hinge antibodies (AHA) toward the neoepitopes. The AHA can act as surrogate Fc and reintroduce the properties of the Fc that are otherwise lacking in antibody fragments. While this response is desired during the natural process of fighting disease, it is commonly unwanted for therapeutic antibody fragments. In our study, we identify a truncation in the lower hinge region of the antibody that maintains efficient prot

SUBMITTER: Kim HS 

PROVIDER: S-EPMC5098439 | biostudies-literature | 2016 Nov/Dec

REPOSITORIES: biostudies-literature